Ignite Creation Date:
2024-05-06 @ 2:25 AM
Last Modification Date:
2024-10-26 @ 11:18 AM
Study NCT ID:
NCT02042014
Status:
COMPLETED
Last Update Posted:
2019-06-18
First Post:
2014-01-17
Brief Title:
Open-label Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study A2301E1 in Japan
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
An Open-label Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study A2301E1 in Japan and Are Judged by the Investigator to Benefit From Continued QTI571 Treatment
Status:
COMPLETED
Status Verified Date:
2019-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To provide continued treatment to Pulmonary Arterial Hypertension PAH patients who are benefitting from treatment with QTI571
Detailed Description:
This was a multi-center open label study to provide continued supply of QTI571 to patients in Japan who were treated in the extension study A2301E1 and were judged by the investigator to benefit from continued QTI571 treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None